Evidence map›Paper›PMID 41330274›Full record

ArticleStem cell research2025

Generation of WTD, a control human iPSC line for genetic research.

Bria L Macklin, Wendy V Runyon, Carissa M Feliciano, Philip H Dierks, Kaitlin R Kelly, Hannah L Watry, Luke M Judge, Bruce R Conklin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bria L MacklinGladstone Institutes, San Francisco, CA, USA.
Wendy V RunyonGladstone Institutes, San Francisco, CA, USA.
Carissa M FelicianoGladstone Institutes, San Francisco, CA, USA.
Philip H DierksGladstone Institutes, San Francisco, CA, USA.
Kaitlin R KellyGladstone Institutes, San Francisco, CA, USA.
Hannah L WatryGladstone Institutes, San Francisco, CA, USA.
Luke M JudgeGladstone Institutes, San Francisco, CA, USA; Department of Pediatrics, University of California, San Francisco, CA, USA.
Bruce R ConklinGladstone Institutes, San Francisco, CA, USA; Department of Ophthalmology, University of California, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA; Innovative Genomics Institute, Berkeley, CA, USA.

Funding

C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approachesR01AG072052 · NIA · J. DAVID GLADSTONE INSTITUTES · PI CONKLIN, BRUCE R · 2024 to 2025
$1.4M
Cellular perturbations to enhance precise therapeutic genome editing to treat FTD/ALSF32AG081085 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MACKLIN, BRIA · 2023 to 2024
$143k
NIA NIH HHS F32 AG081085NIA NIH HHS R01 AG072052
6 · The paper itself

Abstract

The establishment of well characterized control iPSC lines is essential for robust, reproducible research across laboratories. We used CRISPR/Cas9 to derive an isogeneic control line from a patient-derived iPSC line carrying a mutation in the NEFL gene (E396K). After correction of the E396K mutation, UCSFi003-A (WTD) exhibits multi-lineage differentiation potential, a normal karyotype, no large genomic abnormalities, and has consents for public distribution of cells and genomic data.

Indexed as

Induced Pluripotent Stem CellsCell DifferentiationCell LineCRISPR-Cas SystemsHumansMutation

Identifiers

PMID41330274
PMCPMC13354316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.